Adenocarcinoma of lung (disorder)
|
0.400 |
Biomarker
|
disease |
BEFREE |
Heat shock protein 90 (HSP90) is an important chaperone in lung adenocarcinoma, with relevant protein drivers such as EGFR (epidermal growth factor receptor) and EML4-ALK (echinoderm microtubule-associated protein-like protein4 fused to anaplastic lymphoma kinase) depending on it for their correct function, therefore HSP90 inhibitors show promise as potential treatments for lung adenocarcinoma.
|
31370342 |
2019 |
Adenocarcinoma of lung (disorder)
|
0.400 |
Biomarker
|
disease |
BEFREE |
These circulating EV-RNA levels have been found to correlate with disease progression of <i>EML4-ALK</i>-translocated lung adenocarcinoma in patients prescribed ALK-TKI treatment.
|
30658414 |
2019 |
Adenocarcinoma of lung (disorder)
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Concomitant EGFR Mutation and EML4-ALK Rearrangement in Lung Adenocarcinoma Is More Frequent in Multifocal Lesions.
|
31138506 |
2019 |
Adenocarcinoma of lung (disorder)
|
0.400 |
Biomarker
|
disease |
BEFREE |
Dual drive coexistence of EML4-ALK and TPM3-ROS1 fusion in advanced lung adenocarcinoma.
|
29251824 |
2018 |
Adenocarcinoma of lung (disorder)
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Alectinib treatment response in lung adenocarcinoma patient with novel EML4-ALK variant.
|
30133144 |
2018 |
Adenocarcinoma of lung (disorder)
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
It was histologically characterized with micropapillary, lepidic, and papillary subtypes.The mutation rate of EML4-ALK is relatively high in lung adenocarcinoma patients aged<60 years, pathologically characterized with acinar and solid subtypes with mucin secretion.
|
29952952 |
2018 |
Adenocarcinoma of lung (disorder)
|
0.400 |
Biomarker
|
disease |
BEFREE |
The EML4-ALK fusion gene may be a strong oncogene in younger patients with lung adenocarcinoma.
|
29517858 |
2018 |
Adenocarcinoma of lung (disorder)
|
0.400 |
Biomarker
|
disease |
BEFREE |
Oncogenic fusion genes consisting of echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK) can be detected in 5-7% of lung adenocarcinoma cases.
|
30218431 |
2018 |
Adenocarcinoma of lung (disorder)
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To assess the prevalence of EML4-ALK rearrangement gene measured by immunohistochemistry in an unselected population-based consecutive cohort of patients with adenocarcinoma of the lung (ACL), and the correlation with smoking history, thyroid transcription factor 1 (TTF1), gender and age.
|
27943404 |
2017 |
Adenocarcinoma of lung (disorder)
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We identified EML4-ALK gene rearrangement in expanded CTCs from a patient with ALK-positive lung adenocarcinoma.
|
27507192 |
2017 |
Adenocarcinoma of lung (disorder)
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The major driver mutations of lung cancer, EGFR mutations and EML4-ALK fusion, are mainly detected in terminal respiratory unit (TRU)-type lung adenocarcinomas, which typically show lepidic and/or papillary patterns, but are rarely associated with a solid or invasive mucinous morphology.
|
28677170 |
2017 |
Adenocarcinoma of lung (disorder)
|
0.400 |
Biomarker
|
disease |
BEFREE |
Since the discovery of the fusion between EML4 (echinoderm microtubule associated protein-like 4) and ALK (anaplastic lymphoma kinase), EML4-ALK, in lung adenocarcinomas in 2007, and the subsequent identification of at least 15 different variants in lung cancers, there has been a revolution in molecular-targeted therapy that has transformed the outlook for these patients.
|
28872581 |
2017 |
Adenocarcinoma of lung (disorder)
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In addition, the association between MAGE-A expression and the epithelial growth factor receptor (EGFR) amplification and ALK-EML4 rearrangements of patients with LAC were also analysed.
|
27864450 |
2017 |
Adenocarcinoma of lung (disorder)
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A total of 253 patients with advanced lung adenocarcinoma received a pemetrexed-based regimen and were classified on the basis of molecular findings as follows: 102 patients (40.3%) with EGFR mutations, 32 patients (12.6%) with EML4-ALK translocation, three patients (1.2%) with KRAS mutations, 19 patients (7.5%) with ROS1 fusion, and 97 patients (38.3%) with quadruple-negative status.
|
27094798 |
2016 |
Adenocarcinoma of lung (disorder)
|
0.400 |
Biomarker
|
disease |
BEFREE |
CRKL mediates EML4-ALK signaling and is a potential therapeutic target for ALK-rearranged lung adenocarcinoma.
|
27078848 |
2016 |
Adenocarcinoma of lung (disorder)
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Male, current smoker, and EML4-ALK variant 3 indicated poor prognosis among ALK fusion-positive lung adenocarcinomas.
|
26646246 |
2016 |
Adenocarcinoma of lung (disorder)
|
0.400 |
Biomarker
|
disease |
BEFREE |
Oncogenic fusion of anaplastic lymphoma kinase (ALK) with echinoderm microtubule associated protein like 4 protein or other partner genes occurs in 3% to 6% of lung adenocarcinomas.
|
27613526 |
2016 |
Adenocarcinoma of lung (disorder)
|
0.400 |
Biomarker
|
disease |
BEFREE |
Echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusions represent the majority of ALK rearrangements in lung adenocarcinomas and were, until recently, thought to be exclusive to that tumour type.
|
26880345 |
2016 |
Adenocarcinoma of lung (disorder)
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Response to crizotinib in a lung adenocarcinoma patient harboring EML4-ALK translocation with adnexal metastasis: A Case Report.
|
27472693 |
2016 |
Adenocarcinoma of lung (disorder)
|
0.400 |
Biomarker
|
disease |
BEFREE |
Upfront inhibition of both ALK and the kinase MEK enhanced both the magnitude and duration of the initial response in preclinical models of EML4-ALK lung adenocarcinoma.
|
26301689 |
2015 |
Adenocarcinoma of lung (disorder)
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In this study, we found that the lung adenocarcinoma cell line A925L expresses an EML4-ALK gene fusion (variant 5a, E2:A20) and is sensitive to the ALK inhibitors crizotinib and alectinib.
|
25581823 |
2015 |
Adenocarcinoma of lung (disorder)
|
0.400 |
Biomarker
|
disease |
BEFREE |
Droplet Digital PCR for Absolute Quantification of EML4-ALK Gene Rearrangement in Lung Adenocarcinoma.
|
26142544 |
2015 |
Adenocarcinoma of lung (disorder)
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
EML4-ALK rearrangement is detected in 2% to 7% of lung adenocarcinomas, these tumors are sensitive to crizotinib.
|
26045865 |
2015 |
Adenocarcinoma of lung (disorder)
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Analysis of ERBB ligand-induced resistance mechanism to crizotinib by primary culture of lung adenocarcinoma with EML4-ALK fusion gene.
|
25695223 |
2015 |
Adenocarcinoma of lung (disorder)
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although the frequency of EML4-ALK rearrangements is lower in lung SqCC than that in lung adenocarcinomas, their presence may provide additional treatment options in lung SqCC.
|
25527865 |
2014 |